# Ken Kato

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ken-kato/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,223 |
| Field | Esophageal Cancer Research and Treatment |
| h-index | 76 |
| i10-index | 321 |
| Last Known Institution | National Cancer Center |
| OpenAlex ID | https://openalex.org/A5082832235 |
| ORCID iD | https://orcid.org/0000-0002-1733-5072 |
| Works | 834 |

## Researcher papers

- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-oesophageal-squamous/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2](https://scholariq.org/papers/esophageal-cancer-practice-guidelines-2017-edited-by-the-japan-esophageal/)
- [Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1](https://scholariq.org/papers/esophageal-cancer-practice-guidelines-2017-edited-by-the-japan-esophageal-2/)
- [Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma](https://scholariq.org/papers/nivolumab-combination-therapy-in-advanced-esophageal-squamous-cell-carcinoma/)
- [Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus](https://scholariq.org/papers/efficacy-and-safety-of-pembrolizumab-for-heavily-pretreated-patients-with/)
- [Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies](https://scholariq.org/papers/clinical-utility-of-circulating-tumor-dna-sequencing-in-advanced/)
- [Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)](https://scholariq.org/papers/safety-and-efficacy-of-nivolumab-in-combination-with-s-1-capecitabine-plus/)
- [Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study](https://scholariq.org/papers/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or/)
- [Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line/)
- [Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial](https://scholariq.org/papers/circulating-tumor-dna-guided-treatment-with-pertuzumab-plus-trastuzumab-for-her2/)

## Researcher topics

- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [National Cancer Center](https://scholariq.org/institutions/national-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.